EP2044435A2 - Modulatoren von scarb-1 bei der behandlung von akne oder hyperseborrhoea - Google Patents

Modulatoren von scarb-1 bei der behandlung von akne oder hyperseborrhoea

Info

Publication number
EP2044435A2
EP2044435A2 EP07823605A EP07823605A EP2044435A2 EP 2044435 A2 EP2044435 A2 EP 2044435A2 EP 07823605 A EP07823605 A EP 07823605A EP 07823605 A EP07823605 A EP 07823605A EP 2044435 A2 EP2044435 A2 EP 2044435A2
Authority
EP
European Patent Office
Prior art keywords
expression
gene
scarb
activity
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07823605A
Other languages
English (en)
French (fr)
Inventor
Fernand Labrie
Pascal Collette
Isabelle Carlavan
Jérôme AUBERT
Ezéquiel L. CALVO
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP2044435A2 publication Critical patent/EP2044435A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Definitions

  • the invention relates to the identification and use of SCARB-1 receptor modulating compounds for the treatment of acne, as well as skin disorders associated with hyperseborrhoea. It also relates to methods of in vitro diagnosis or prognosis in vitro of these pathologies.
  • Hyperseborrhoeic oily skin is characterized by excessive secretion and excretion of sebum.
  • a level of sebum greater than 200 ⁇ g / cm 2 measured at the forehead is considered to be characteristic of oily skin.
  • Oily skin is often associated with a lack of desquamation, a glowing complexion, a thick skin texture.
  • the excess of sebum can serve as a support for the anarchic development of the saprophytic bacterial flora (P. acnes in particular), and cause the appearance of comedones and / or acne lesions. This stimulation of sebaceous gland production is induced by androgens.
  • Acne is, in fact, a chronic disease of the pilosebaceous follicle under hormonal dependence.
  • a hormonal therapy against acne is a possibility of treatment for women, the goal being to oppose the effects of androgens on the sebaceous gland.
  • estrogens, anti-androgens, or agents that decrease the production of androgens by the ovaries or the adrenal gland are generally used.
  • Antiandrogens used for the treatment of acne include spironolactone, cyproterone acetate, and flutamide. However, these agents have severe side effects. Thus, any pregnancy must be absolutely prevented, particularly because of a risk of feminization for the male fetus. These agents are prohibited in male patients.
  • the Applicant has now discovered that the gene coding for the SCARB-1 receptor is expressed in the human sebaceous glands, and that its expression is regulated by androgens, in vivo, in a mouse preputial gland model. It therefore proposes to target the SCARB-1 gene or its expression product, to prevent or improve acne phenomena, as well as the skin disorders associated with hyperseborrhoea, especially the appearance of oily skin.
  • acne we mean all forms of acne, namely in particular vulgar acne, comedonal, polymorphic, nodulocystic acne, conglobata, or secondary acne such as solar acne, drug or professional.
  • the Applicant also proposes diagnostic methods, in vitro or prognostic in vitro, based on the detection of the level of expression or activity of SCARB-1.
  • Scavenger receptors are cell surface proteins, which are typically found on macrophages and bind to various types of modified lipoproteins, such as low density lipoproteins (LDL).
  • LDL low density lipoproteins
  • This family of transmembrane receptors which has a great structural diversity, is involved in endocytosis and phagocytosis of apoptotic cells and bacteria, as well as in cell adhesion. These receptors would also intervene in the deposition of LDL cholesterol macrophages at the coronary artery walls, during the early phases of the formation of an atherosclerotic plaque.
  • SCARB-1 scavenger receptor class B, member 1
  • SRB-1 also referred to as SRB-1, or Cla-1
  • SRB-1 belongs to the family of "scavenger” receptors, class B, and is a lipoprotein receptor. high-density, which mediates the incorporation of cholesterol into the cells.
  • SRB-I can also serve as a receptor for non-HDL lipoproteins and would play an important role in the reverse transport of cholesterol. Expression of this gene would be induced by testosterone in macrophages and hepatocytes in culture (Langer et al, Biochem Biophys Res Commun 2002, 296 (5): 1051-1057).
  • Millena et al (Mol CeII Endocrinol, 2004, 224 (1-2): 29-39) have, in turn, shown that an increase in androgen production in response to TGF ⁇ was associated with high levels of mRNA. SCARB-1.
  • SCARB-1 gene or "SCARB-1 nucleic acid” means the gene or nucleic sequence encoding a SCARB-1 transmembrane receptor. If the targeted target is preferably the human gene or its expression product, the invention can also use cells expressing a heterologous SCARB-1 receptor, by genomic integration or transient expression of an exogenous nucleic acid sequence. encoding the enzyme (eg an enzyme from another organism). A human SCARB-1 cDNA sequence is reproduced in the appendix (SEQ ID No. 1). This is the NM005505 sequence whose coding portion is from nucleic acid 70 to 1599. Diagnostic applications
  • An object of the invention relates to an in vitro method for diagnosing or monitoring the progression of acne lesions or skin disorder associated with hyperseborrhea in a subject, comprising comparing the expression or activity of the subject.
  • SCARB-1 the expression of its gene or the activity of at least one of its promoters, in a biological sample of a subject relative to a biological sample of a control subject.
  • the expression of the protein can be determined by assaying the SCARB-1 protein by radioimmunoassay, for example by ELISA assay.
  • Another method, especially for measuring the expression of the gene is to measure the amount of corresponding mRNA by any method as described above.
  • An assay of the activity of SCARB-1 may also be considered.
  • control is a "healthy” subject.
  • control subject refers to the same subject at a different time, which preferably corresponds to the beginning of the treatment (To ).
  • This measurement of the difference in expression or activity of SCARB-1, or expression of its gene or activity of at least one of its promoters makes it possible in particular to monitor the efficacy of a treatment, in particular treatment with a modulator of SCARB-1, as envisaged above or by another treatment against acne or a skin disorder associated with hyperseborrhoea.
  • follow-up can reassure the patient as to the appropriateness, or necessity, of continuing this treatment.
  • Another aspect of the present invention relates to an in vitro method for determining susceptibility of a subject to develop acne lesions or skin disorder associated with hyperseborrhoea, comprising comparing SCARB expression or activity. -1, the expression of its gene or the activity of at least one of its promoters, in a biological sample of a subject relative to a biological sample of a control subject.
  • the expression of the protein can be determined by assaying the SCARB-1 protein by radioimmunoassay, for example by ELISA assay.
  • Another method, especially for measuring the expression of the gene is to measure the amount of corresponding mRNA by any method as described above.
  • An assay of the activity of SCARB-1 may also be considered.
  • the subject tested here is an asymptomatic subject, having no skin disorder associated with hyperseborrhoea or acne.
  • the subject "control” in this method means a subject or a "healthy” reference population. The detection of this susceptibility allows the establishment of a preventive treatment and / or increased monitoring of signs related to acne or a skin disorder associated with hyperseborrhoea.
  • the biological sample tested may be any sample of biological fluid or a sample of a biopsy.
  • the sample may nevertheless be a preparation of skin cells, obtained for example by desquamation or biopsy. It can also be sebum.
  • An object of the invention is an in vitro method for screening candidate compounds for the preventive and / or curative treatment of acne or skin disorders associated with hyperseborrhoea, comprising determining the capacity of a compound to modulate the expression or activity of the SCARB-1 receptor or the expression of its gene or the activity of at least one of its promoters, said modulation indicating the utility of the compound for the preventive or curative treatment of acne or skin disorders associated with hyperseborrhoea.
  • the method therefore makes it possible to select compounds capable of modulating the expression or the activity of the SCARB-1 receptor, or the expression of its gene, or the activity of at least one of its promoters.
  • the invention relates to an in vitro method for screening candidate compounds for the preventive and / or curative treatment of acne or skin disorders associated with hyperseborrhoea, comprising the following steps: a. preparation of at least two biological samples or reaction mixtures; b. contacting one of the samples or reaction mixtures with one or more of the test compounds; vs. measuring the expression or the activity of the SCARB-1 protein, the expression of its gene or the activity of at least one of its promoters, in the biological samples or reaction mixtures; d.
  • modulation is meant any effect on the expression or the activity of the receptor, the expression of its gene or the activity of at least one of its promoters, namely possibly a stimulation (ie an agonist activity), but preferably a partial or complete inhibition (ie an antagonistic activity).
  • a stimulation ie an agonist activity
  • a partial or complete inhibition ie an antagonistic activity
  • expression of a protein means the amount of that protein
  • protein activity is meant its biological activity
  • promoter activity is meant the ability of this promoter to trigger the transcription of the coded DNA sequence downstream of this promoter (and thus indirectly the synthesis of the corresponding protein).
  • the compounds tested can be of any type. They can be of natural origin or have been produced by chemical synthesis. It can be a library of structurally defined chemical compounds, compounds or uncharacterized substances, or a mixture of compounds. Various techniques can be implemented to test these compounds and to identify the compounds of therapeutic interest, modulators of SCARB-1 receptor expression or activity.
  • the biological samples are cells transfected with a reporter gene operably linked to all or part of the promoter of the SCARB-1 gene, and step c) described above consists in measuring the expression said reporter gene.
  • the reporter gene may in particular code for an enzyme which, in the presence of a given substrate, leads to the formation of colored products, such as CAT (chloramphenicol acetyltransferase), GAL (beta galactosidase), or GUS (beta glucuronidase). It may also be the gene for luciferase or GFP (Green Fluorescent Protein).
  • the assay of the protein encoded by the reporter gene, or its activity, is carried out conventionally, by colorimetric, fluorometric or chemiluminescent techniques, among others.
  • the biological samples are cells expressing the SCARB-1 gene, and the step c) described above consists in measuring the expression of said gene.
  • the cell used here can be of any type. It can be a cell expressing the gene
  • SCARB-1 endogenously such as a liver cell, an ovarian cell, or more preferably a sebocyte. It is also possible to use organs of human or animal origin, such as, for example, the preputial gland, clitoral gland or the sebaceous gland of the skin. It can also be a cell transformed with a heterologous nucleic acid, encoding a SCARB-1 receptor, preferably human, or mammalian.
  • host cell systems such as, for example, Cos-7, CHO, BHK, 3T3, HEK293 cells.
  • the nucleic acid can be stably or transiently transfected by any method known to those skilled in the art, for example by calcium phosphate, DEAE-dextran, liposome, virus, electroporation, or microinjection.
  • the expression of SCARB-1 can be determined by measuring the transcription rate of said gene, or its translation rate.
  • transcription rate of a gene is meant the amount of corresponding mRNA produced.
  • translation rate of a gene is meant the amount of corresponding protein produced.
  • RNAs of a gene of interest are the most common (Northern blot, RT-PCR, RNase protection). It may be advantageous to use detection markers, such as fluorescent, radioactive, enzymatic or other ligands (e.g., avidin / biotin).
  • detection markers such as fluorescent, radioactive, enzymatic or other ligands (e.g., avidin / biotin).
  • the expression of the gene can be measured by real-time PCR or by RNase protection.
  • RNase protection is meant the detection of a known mRNA from the poly (A) RNAs of a tissue that can be done by means of specific hybridization with a labeled probe.
  • the probe is a complementary RNA labeled (radioactive) messenger to look for. It can be constructed from a known mRNA whose cDNA, after RT-PCR, has been cloned into a phage. RNA-poly (A) of the tissue where the sequence is to be searched is incubated with this probe under slow hybridization conditions in a liquid medium. RNA: RNA hybrids are formed between the desired mRNA and the antisense probe. The hybrid medium is then incubated with a mixture of ribonucleases specific for single-stranded RNA, so that only the hybrids formed with the probe can resist this digestion. The digestion product is then deproteinized and repurified, before being analyzed by electrophoresis. The labeled hybrid RNAs are detected by autoradiography.
  • the translation rate of the gene is evaluated for example by immunological assay of the product of said gene.
  • the antibodies used for this purpose may be of polyclonal or monoclonal type. Their production is based on conventional techniques.
  • a polyclonal anti-SCARB-1 antibody can, inter alia, be obtained by immunizing an animal such as a rabbit or a mouse, using the entire enzyme, sampling and then depleting the antiserum according to methods in themselves known to those skilled in the art.
  • a monoclonal antibody can, inter alia, be obtained by the conventional method of Kohler and Milstein (Nature (London), 256: 495-497 (1975)). Other methods of preparing monoclonal antibodies are also known.
  • monoclonal antibodies can be produced by expression of a cloned nucleic acid from a hybridoma.
  • Antibodies can also be produced by the phage display technique, by introducing antibody cDNAs into vectors, which are typically filamentous phages that have V gene libraries on the surface of the phage. (for example fUSE5 for E.coli).
  • the immunoassay can be carried out in solid phase or in homogeneous phase; in a time or in two stages; sandwich method or competitive method, by way of non-limiting examples.
  • the capture antibody is immobilized on a solid phase.
  • solid phase it is possible to use microplates, in particular polystyrene microplates, or particles or solid beads, paramagnetic beads.
  • ELISA assays radioimmunoassays, or any other detection technique can be used to reveal the presence of the antigen-antibody complexes formed.
  • the characterization of antigen / antibody complexes, and more generally isolated or purified but also recombinant proteins (obtained in vitro and in vivo) can be performed by mass spectrometry analysis. This identification is made possible thanks to the analysis (determination of the mass) of the peptides generated by the enzymatic hydrolysis of the proteins (trypsin in general). In general, the proteins are isolated according to methods known to those skilled in the art, prior to enzymatic digestion.
  • Peptide analysis in the form of hydrolyzate is carried out by peptide separation by HPLC (nano-HPLC) based on their physicochemical properties (reverse phase).
  • HPLC nano-HPLC
  • the determination of the mass of the peptides thus separated is carried out by ionization of the peptides and either by direct coupling to the mass spectrometer (electrospray mode ESI) or after deposition and crystallization in the presence of a matrix known to those skilled in the art ( analysis in MALDI mode).
  • the proteins are then identified through the use of appropriate software (eg Mascot).
  • step a) described above consists in preparing reaction mixtures each comprising a SCARB-1 receptor and step c) described above consists in measuring the binding capacity of the compound to the receptor. and the modulation of its activity.
  • the SCARB-1 receptor can be produced according to standard techniques using Cos-7, CHO, BHK, 3T3, HEK293 cells. It can also be produced using microorganisms such as bacteria (for example E. coli or B. subtilis), yeasts (for example Saccharomyces, Pichia) or insect cells, such as Sf9 or Sf21.
  • Activity measurement refers to the determination of cell adhesion activity, transporter activity, apoptotic activity, activity in lipid metabolism, signal transduction and / or cytokine secretion. .
  • An exemplary detection method is presented in TIAN et al., Bio Env Sci, 2005, 18: 265-272.
  • This method of detecting receptor activity is based on the use of fluorescently labeled human lipoproteins, Dil-lipoproteins (DiI-AcLDL and DiLHDL).
  • the measurement of the binding of the Dil-lipoproteins is carried out by incubation of Sf9 cells, previously transformed with a baculovirus, with a MOI (multiplicity of infection) of 5 with baculoviruses which may or may not have the coding sequence for the SCARB1 receptor, in 50 ⁇ L of culture medium containing 0.2% BSA (bovine serum albumin) with different concentrations of DiL-AcLDL and DiI-HDL at room temperature for a few hours.
  • BSA bovine serum albumin
  • the subject of the invention is also the use of a SCARB-1 human receptor modulator obtainable according to one of the methods described above for the preparation of a medicinal product intended for preventive and / or curative treatment. acne, or skin disorders associated with hyperseborrhoea.
  • a method of preventive and / or curative treatment of acne, or skin disorders associated with hyperseborrhoea comprising administering a therapeutically effective amount of a modulator of the human SCARB-1 receptor, to a patient in need of such treatment.
  • the invention finally relates to the cosmetic use of a SCARB-1 receptor modulator, for the aesthetic treatment of oily skin.
  • the modulator is a receptor antagonist.
  • antagonist refers to a compound or chemical substance that substantially eliminates or reduces the activity of the SCARB-1 receptor.
  • substantially means a reduction of at least 25%, preferably at least 35%, more preferably at least 50%, and more preferably at least 70% or 90%. More particularly, it may be a compound that interacts with, and blocks, binding of the receptor with its ligand.
  • a preferred inhibitor interacts with the receptor in solution at inhibitor concentrations of less than 1 ⁇ M, preferably less than 0.1 ⁇ M, more preferably less than 0.01 ⁇ M.
  • the modulator compound may also be a polypeptide, an antisense DNA or RNA polynucleotide, an si-RNA, or a PNA ("Peptide nucleic acid", a polypeptide chain substituted with purine and pyrimidine bases, whose spatial structure mimes that of DNA and allows hybridization to it).
  • PNA Peptide nucleic acid
  • the modulator compound may be a SCARB-1 anti-receptor inhibitory antibody, preferably a monoclonal antibody.
  • an inhibitory antibody is administered in an amount sufficient to obtain a plasma concentration of about 0.01 ⁇ g per ml to about 100 ⁇ g / ml, preferably from about 1 ⁇ g per ml to about 5 ⁇ g / ml.
  • it may be an antibody that binds to the collagenic extracellular domain of the receptor, which plays a role in ligand binding (Acton, 1993, J. Biol Chem 268 (5): 3530-7).
  • neutralizing antibodies are also described in WO04 / 80385.
  • Other neutralizing antibodies are known in the art (see, for example, Frolov, 2000, J. Biol Chem 275 (17): 12769-12780).
  • the invention comprises the use of such SCARB-1 receptor antagonist compounds for the preventive and / or curative treatment of acne, or any skin disorder associated with hyperseborrhoea.
  • Other modulator compounds identified by the screening method described above are also useful.
  • the modulating compounds are formulated within a pharmaceutical composition, in association with a pharmaceutically acceptable vehicle.
  • These compositions may be administered, for example, orally, parenterally, or topically.
  • the pharmaceutical composition is applied topically.
  • the pharmaceutical composition can be in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid vesicles or polymers for controlled release.
  • the pharmaceutical composition may be in the form of solutions or suspensions for infusion or for injection.
  • the pharmaceutical composition is more particularly intended for the treatment of skin and mucous membranes and may be in the form of ointments, creams, milks, ointments, powders, soaked swabs, solutions, gels , sprays, lotions or suspensions. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches or hydrogels allowing controlled release.
  • This composition for topical application may be in anhydrous form, in aqueous form or in the form of an emulsion.
  • the pharmaceutical composition is in the form of a gel, a cream or a lotion.
  • the composition may comprise a SCARB-1 modulator content ranging from 0.001 to 10% by weight, especially from 0.01 to 5% by weight relative to the total weight of the composition.
  • the pharmaceutical composition may further contain inert additives or combinations of these additives, such as:
  • preserving agents such as esters of parahydroxybenzoic acid; stabilizing agents;
  • osmotic pressure modifying agents emulsifying agents
  • antioxidants such as alpha-tocopherol, butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal chelators.
  • Figure 1 shows the measurement of SCARB-1 gene expression in male gonadectomized mice treated with vehicle, DHT, DHEA or combination of
  • DHEA-Flutamide for a period of 7 days once a day (long-term treatment).
  • GDX mice gonadectomized and treated with the vehicle
  • DHT gonadectomized mice treated with Dihydrotestosterone (androgen receptor agonist)
  • DHEA gonadectomized mice treated with dihydroepiandrosterone (precursor of steroid hormones, in the preputial glands metabolized to active androgen)
  • DHEA-FIu gonadectomized mice treated with a combination of
  • Dihydroepiandrosterone and Flutamide which blocks the effects of DHT and DHEA agonists.
  • Figure 2 is a graph of a kinetic study of 15 to 96 hours.
  • the dashed blue line represents expression in gonadectomized mice following treatment with DHT at time zero.
  • the red line represents expression in gonadectomized mice without treatment with DHT.
  • Level of expression level of expression of mRNA
  • RNA samples were prepared from the sebaceous glands and from the epidermis. Gene expression was analyzed on an Affymetrix station (microfluidic module, hybridization oven, scanner, computer) following the protocols provided by the company. In short, the total RNA isolated from the tissues is transcribed into cDNA. From the double-stranded cDNA a biotin labeled cRNA is synthesized using T7 polymerase and a precursor NTP conjugated to biotin. The cRNAs are then fragmented into small fragments.
  • Affymetrix station microfluidic module, hybridization oven, scanner, computer
  • the calculation of the significance of the expression is based on the analysis of the signals that are obtained following the hybridization of the cRNA of a given gene with a oligonucleotide hybridizing perfectly ("perfect match") versus an oligonucleotide which contains a single mismatch in the central region of the oligonucleotide (see Table 1)
  • Table 1 Measurement of the expression of SCARB-1 in the epidermis and in the human sebaceous gland by using the Affymetrix technology.
  • SCARB-1 receptor is well expressed in both tissues (sebaceous gland, epidermis). Differential analysis between expression in the human sebaceous gland and human repornm shows that SCARB-1 is expressed more strongly in the human sebaceous gland.
  • mice show differentiation of the sebocyte type and are used as an experimental model of the sebaceous gland. They are of sufficient size to allow isolation of RNA without the use of microdissection technologies.
  • Gene expression was analyzed using the Affymetrix technology described above.
  • SCARB-1 mRNA is induced by chronic treatment for 7 days with androgens in the preputial gland.
  • mice Male gonadectomized mice treated with the vehicle, or DHT. A kinetic study of gene expression from 15 minutes to 96 hours was performed. For this, the preputial glands were removed for up to 4 days (single androgenic treatment - observation of short-term kinetics), RNA was isolated, and gene expression was analyzed by the Affymetrix technique ( Figure 2).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP07823605A 2006-07-19 2007-07-18 Modulatoren von scarb-1 bei der behandlung von akne oder hyperseborrhoea Withdrawn EP2044435A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653034A FR2904004B1 (fr) 2006-07-19 2006-07-19 Modulateurs de scarb-1 dans le traitement de l'acne ou de l'hyperseborrhee
PCT/FR2007/051686 WO2008009859A2 (fr) 2006-07-19 2007-07-18 Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée

Publications (1)

Publication Number Publication Date
EP2044435A2 true EP2044435A2 (de) 2009-04-08

Family

ID=37668112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07823605A Withdrawn EP2044435A2 (de) 2006-07-19 2007-07-18 Modulatoren von scarb-1 bei der behandlung von akne oder hyperseborrhoea

Country Status (5)

Country Link
US (1) US20090246776A1 (de)
EP (1) EP2044435A2 (de)
CA (1) CA2656844A1 (de)
FR (1) FR2904004B1 (de)
WO (1) WO2008009859A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938337A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de mcam dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938333A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de cidea dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938336A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de gos2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654013A (en) * 1995-03-13 1997-08-05 Taylor; Lesli A. Method for treating rosacea
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5965790A (en) * 1997-03-06 1999-10-12 Millennium Pharmaceuticals, Inc. SR-BI regulatory sequences and therapeutic methods of use
US5998141A (en) * 1997-07-10 1999-12-07 Millennium Pharmaceuticals, Inc. Intronic and polymorphic SR-BI nucleic acids and uses therefor
WO2002095034A2 (en) * 2001-05-23 2002-11-28 Cytochroma Inc. A retinoic acid metabolizing cytochrome p450
WO2005100998A2 (de) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008009859A3 *

Also Published As

Publication number Publication date
US20090246776A1 (en) 2009-10-01
FR2904004A1 (fr) 2008-01-25
WO2008009859A2 (fr) 2008-01-24
FR2904004B1 (fr) 2008-09-05
CA2656844A1 (fr) 2008-01-24
WO2008009859A3 (fr) 2008-03-13

Similar Documents

Publication Publication Date Title
FR2938341A1 (fr) Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938338A1 (fr) Modulateurs de l'acetyl-coenzyme a acyltransferase 1 ou 2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
EP2044435A2 (de) Modulatoren von scarb-1 bei der behandlung von akne oder hyperseborrhoea
EP2046975A2 (de) Modulatoren von hsd17b7 bei der behandlung von akne oder hyperseborrhoea
EP2046974A2 (de) Modulatoren von sc4mol bei der behandlung von akne oder hyperseborrhoea
WO2008009854A2 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
FR2938333A1 (fr) Modulateurs de cidea dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2008009857A2 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
FR2938342A1 (fr) Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
EP2046979A2 (de) Modulatoren von elovl5 bei der behandlung von akne oder hyperseborrhoea
FR2938334A1 (fr) Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
EP2046980A2 (de) Modulatoren der lanosterol-synthetase bei der behandlung von akne oder hyperseborrhoe
FR2938340A1 (fr) Modulateurs de la carnitine octanoyltransferase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938339A1 (fr) Modulateurs de la pctp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938337A1 (fr) Modulateurs de mcam dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938335A1 (fr) Modulateurs de l'isovaleryl-coenzyme a dehydrogenase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938336A1 (fr) Modulateurs de gos2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938343A1 (fr) Ciblage de modulateurs de cyp2b15 et/ou gpd1 pour le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090605

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20121217